• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

ADA Logo in Chicago American Diabetes Association 85th Scientific Sessions

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., Glucotrack, Insulet, LifePlus, mannkind, Medtronic, minimed, modularmedical, PharmaSens, Senseonics, Sequel Med Tech, SiBionics, Tandem Diabetes Care, Vaxess Technologies

Dexcom continues advances in AI for CGM, type 2 diabetes awareness

June 22, 2025 By Sean Whooley

Dexcom and Oura partnered to combine insights using the Dexcom Stelo CGM and Oura ring with a mobile app, all pictured here alongside a meal.

As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and […]

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology Tagged With: ADA 2025, Dexcom

Dexcom shares U.S. report on CGM benefits for type 2 diabetes

June 21, 2025 By Sean Whooley

Dexcom G7 CGM Apple Watch direct-to-watch

Dexcom (Nasdaq:DXCM) has shared a new report highlighting access and attitudes toward type 2 diabetes in the U.S. The company released its report — “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” — ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: ADA 2025, Dexcom

Dexcom has a Class I CGM receiver recall

June 17, 2025 By Sean Whooley

Dexcom One+ CGM phone and receiver (1)

The FDA’s recall database today posted notices related to a Class I recall for continuous glucose monitor (CGM) components made by Dexcom (Nasdaq:DXCM). Dexcom’s recalls relate to its Dexcom One and One+ offerings and the G6 and G7 CGMs. The One and One+ systems, which are mainly the company’s commercial CGM offering outside the U.S., feature […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Recalls, Regulatory/Compliance, Technology Tagged With: Dexcom, FDA

Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

June 10, 2025 By Sean Whooley

Insulet Omnipod 5 with Dexcom G7

Insulet (Nasdaq:PODD) today announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone. Omnipod 5, the first FDA-cleared tubeless automated insulin delivery system, communicates with a CGM, such as G7. It […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Insulet

Dexcom promotes Jake Leach to president role

May 13, 2025 By Sean Whooley

Jake Leach Dexcom COO

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO. Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel Moves

Dexcom expands Oura partnership with Stelo integration

May 6, 2025 By Sean Whooley

Dexcom and Oura partnered to combine insights using the Dexcom Stelo CGM and Oura ring with a mobile app, all pictured here alongside a meal.

Dexcom (NASDAQ:DXCM) announced today that it expanded its partnership with Oura, officially launching an integration with Stelo. Stelo, the company’s FDA-cleared over-the-counter (OTC) glucose biosensor, now gives users 24/7 glucose insights via the Oura app. Oura’s new in-app metabolic health feature, Glucose, now gives Oura members a deeper understanding of how dietary choices impact health. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Oura

Analysts are high on Dexcom after Q1 results, $750M repurchase program

May 1, 2025 By Sean Whooley

Dexcom updated Logo

Dexcom (Nadsaq:DXCM) shares rose after hours today on first-quarter results that came in mixed compared to the consensus forecast. Shares of DXCM ticked up 3% to $72.30 apiece in post-market trading on Thursday. However, before hours on Friday, shares fell 1.6% to $70.26 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported profits of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

Dexcom wins FDA nod for 15-day CGM

April 10, 2025 By Sean Whooley

Dexcom G7 15-day CGM (1)

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system. The clearance covers people over the age of 18 years old in the U.S. It makes the G7, Dexcom’s latest-generation CGM, the longest-lasting wearable CGM, according to the company. San Diego–based Dexcom submitted its 15-day G7 CGM to the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Dexcom, FDA

Dexcom picks longtime Masimo exec as next CCO

March 25, 2025 By Sean Whooley

Jon Coleman Dexcom Chief Commercial Officer CCO

Dexcom (Nasdaq:DXCM) announced today that it appointed Jon Coleman as its new chief commercial officer (CCO). Coleman assumes responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. He takes over for Teri Lawver, who in October announced her plans to retire as CCO of the continuous glucose monitor (CGM) maker. At […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel Moves

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 18
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS